Editas Medicine Management
Management criteria checks 3/4
Editas Medicine's CEO is Gilmore O’Neill, appointed in Jun 2022, has a tenure of 1.83 years. total yearly compensation is $2.39M, comprised of 26.8% salary and 73.2% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $492.15K. The average tenure of the management team and the board of directors is 1.4 years and 4.3 years respectively.
Key information
Gilmore O’Neill
Chief executive officer
US$2.4m
Total compensation
| CEO salary percentage | 26.8% |
| CEO tenure | 1.8yrs |
| CEO ownership | 0.1% |
| Management average tenure | 1.4yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%
Apr 23
Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Mar 09Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)
Dec 15Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
May 10Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Jan 19Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline
Oct 18Editas Medicine started at neutral at BofA due to competition in gene editing programs
Sep 29We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely
Sep 13Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies
Aug 23Editas Medicine Q2 2022 Earnings Preview
Aug 02Baisong Mei joins Editas Medicine as Chief Medical Officer
Jul 18Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?
Jun 12Editas: Tackling Rare Eye Disease With Use Of Crispr Technology
Jun 06Editas: The Unforeseen Detrimental Effect Of Patent Win
Mar 25Editas: CRISPR Gene Editing Biotech With Promising Future
Mar 15Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
Feb 25Editas Medicine: A Gene-Editing Company That Has Fallen Significantly In Price Recently
Dec 28Editas - The Introvert Crispr Biotech Too Shy To Flex Its Muscles
Dec 15Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation
Nov 17Editas: Data Was Eagerly Anticipated But Failed To Impress
Nov 03Is Editas Medicine (NASDAQ:EDIT) Using Too Much Debt?
Sep 07Editas: Gene Therapy Specialist Leading The Way In Eye Disease
Aug 27Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation
Aug 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$641k | -US$153m |
| Sep 30 2023 | n/a | n/a | -US$195m |
| Jun 30 2023 | n/a | n/a | -US$206m |
| Mar 31 2023 | n/a | n/a | -US$219m |
| Dec 31 2022 | US$9m | US$356k | -US$220m |
Compensation vs Market: Gilmore's total compensation ($USD2.39M) is about average for companies of similar size in the US market ($USD2.37M).
Compensation vs Earnings: Gilmore's compensation has been consistent with company performance over the past year.
CEO
Gilmore O’Neill (59 yo)
1.8yrs
Tenure
US$2,392,309
Compensation
Dr. Gilmore O’Neill, M. B., M. M.SC., serves as Member of Scientific Advisory Board of AavantiBio, Inc. since February 2022. He is President & CEO of Editas Medicine, Inc. from June 01, 2022 and serves as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.8yrs | US$2.39m | 0.11% $ 492.2k | |
| CFO & Executive VP | less than a year | US$2.69m | 0% $ 0 | |
| Executive VP & Chief Scientific Officer | less than a year | US$1.73m | 0% $ 0 | |
| Executive VP & Chief Medical Officer | 1.8yrs | US$1.14m | 0.041% $ 174.2k | |
| Co-Founder & Scientific Advisory Board Member | 11.3yrs | no data | no data | |
| Co-Founder & Scientific Advisory Board Member | 11.3yrs | no data | no data | |
| Corporate Communications & Investor Relations | no data | no data | no data | |
| Executive VP & General Counsel | no data | no data | no data | |
| Executive VP & Chief People Officer | 1.1yrs | no data | no data | |
| Executive VP and Chief Commercial & Strategy Officer | less than a year | no data | no data |
1.4yrs
Average Tenure
59yo
Average Age
Experienced Management: EDIT's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | no data | US$2.39m | 0.11% $ 492.2k | |
| Co-Founder & Scientific Advisory Board Member | no data | no data | no data | |
| Co-Founder & Scientific Advisory Board Member | no data | no data | no data | |
| Independent Chairman of the Board | 2.6yrs | US$238.24k | 0% $ 0 | |
| Independent Director | 7.8yrs | US$208.06k | 0% $ 0 | |
| Independent Director | 6.9yrs | US$210.56k | 0.0024% $ 10.4k | |
| Independent Lead Director | 6.2yrs | US$231.07k | 0.028% $ 118.5k | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Independent Director | 5.2yrs | US$213.06k | 0% $ 0 | |
| Independent Director | 2.5yrs | US$215.06k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$205.56k | 0% $ 0 |
4.3yrs
Average Tenure
63.5yo
Average Age
Experienced Board: EDIT's board of directors are considered experienced (4.3 years average tenure).